These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22232427)

  • 1. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
    Xu C; Ogburn ET; Guo Y; Desta Z
    Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
    Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
    Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
    Ward BA; Gorski JC; Jones DR; Hall SD; Flockhart DA; Desta Z
    J Pharmacol Exp Ther; 2003 Jul; 306(1):287-300. PubMed ID: 12676886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
    Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
    J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.
    Ogburn ET; Jones DR; Masters AR; Xu C; Guo Y; Desta Z
    Drug Metab Dispos; 2010 Jul; 38(7):1218-29. PubMed ID: 20335270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism.
    Crane AL; Klein K; Zanger UM; Olson JR
    Toxicology; 2012 Mar; 293(1-3):115-122. PubMed ID: 22281205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index.
    Jiang F; Desta Z; Shon JH; Yeo CW; Kim HS; Liu KH; Bae SK; Lee SS; Flockhart DA; Shin JG
    Br J Clin Pharmacol; 2013 Jan; 75(1):244-53. PubMed ID: 22554354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.
    Xu C; Quinney SK; Guo Y; Hall SD; Li L; Desta Z
    Drug Metab Dispos; 2013 Dec; 41(12):2004-11. PubMed ID: 23846872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
    Casabar RC; Wallace AD; Hodgson E; Rose RL
    Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
    Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
    Lau AJ; Chang TK
    Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
    Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
    Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
    Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ
    Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artemisinin--a possible CYP2B6 probe substrate?
    Asimus S; Ashton M
    Biopharm Drug Dispos; 2009 Jul; 30(5):265-75. PubMed ID: 19562679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
    Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
    J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity.
    Bumpus NN; Hollenberg PF
    Mol Pharmacol; 2008 Oct; 74(4):990-9. PubMed ID: 18621926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.
    Court MH; Almutairi FE; Greenblatt DJ; Hazarika S; Sheng H; Klein K; Zanger UM; Bourgea J; Patten CJ; Kwara A
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4145-52. PubMed ID: 24820076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
    Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
    Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes.
    Bae SK; Cao S; Seo KA; Kim H; Kim MJ; Shon JH; Liu KH; Zhou HH; Shin JG
    Drug Metab Dispos; 2008 Aug; 36(8):1679-88. PubMed ID: 18474675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
    Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
    Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.